"Bank of America raised its price target on Hims & Hers to $25 from $21, maintaining a Neutral rating. The FDA's procedural step to evaluate wellness peptides could open new revenue doors for the telehealth platform."
"BofA's revised target reflects the optionality the FDA's peptide review creates for Hims & Hers, allowing the company to repurpose GLP-1 capacity toward other peptides, aligning with its ambitions around longevity and preventative medicine."
"Hims & Hers has seen a 29% surge in stock price recently, recovering from a rough stretch that saw a 25% decline year-to-date. The stock trades near the new $25 target, indicating a 'watch and wait' strategy."
Bank of America increased Hims & Hers' price target from $21 to $25 while maintaining a Neutral rating. The FDA's evaluation of wellness peptides could create new revenue opportunities for the telehealth platform. Analysts view this as a positive development, allowing the company to repurpose existing GLP-1 manufacturing capacity. Hims & Hers has seen a 29% stock surge recently, recovering from a previous decline. The company reported over 2.5 million subscribers and significant revenue growth, with expectations for continued increases in 2026.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]